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ﺍﻟﻤﻠﺨﺺ
ﺯﺭﺍﻋﺔﺍﻟﺨﻼﻳﺎﺍﻟﺠﺬﻋﻴﺔ،ﺃﻭﻣﺎﻳﻌﺮﻑﺃﻳﻀًﺎﺑﺰﺭﺍﻋﺔﻧﻘﻲﺍﻟﻌﻈﻢ،ﺗﺴﺘﺨﺪﻡﻟﻌﻼﺝﻋﺪﺩ
ﻣﻦﺳﺮﻃﺎﻧﺎﺕﺍﻟﺪﻡ،ﻭﻛﺬﻟﻚﺃﻣﺮﺍﺽﺃﺧﺮﻯ.ﻭﻣﺼﺎﺩﺭﺍﻟﺨﻼﻳﺎﺍﻟﺠﺬﻋﻴﺔﺍﻟﺘﻲﺗﺴﺘﺨﺪﻡ
ﻣﻦﺍﻟﻤﺘﺒﺮﻉﺛﻼﺛﺔﻭﻫﻲ:ﻧﺨﺎﻉﺍﻟﻌﻈﻢﺃﻭﺍﻟﺨﻼﻳﺎﺍﻟﺠﺬﻋﻴﺔﻣﻦﺍﻟﺪﻡﺍﻟﻤﺤﻔﺰﺓﺑﻌﺎﻣﻞ
ﺗﻨﺸﻴﻂﻟﻨﺨﺎﻉﺍﻟﻌﻈﻢﺃﻭﺗﺠﻤﻴﻊﺍﻟﺨﻼﻳﺎﺍﻟﺠﺬﻋﻴﺔﻣﻦﺍﻟﺤﺒﻞﺍﻟﺴﺮﻱﻣﺒﺎﺷﺮﺓﺑﻌﺪ
ﺍﻟﻮﻻﺩﺓ.ﺇﻥﺃﻭﻝﻃﺮﻳﻘﺔﻟﺘﺠﻤﻴﻊﺍﻟﺨﻼﻳﺎﺍﻟﺠﺬﻋﻴﺔﻣﻦﻧﺨﺎﻉﺍﻟﻌﻈﻢﺗﻤﺖﻋﻦﻃﺮﻳﻖ
ﺍﻟﺴﺤﺐﺑﺈﺑﺮﺧﺎﺻﺔﻣﻦﻋﻈﻢﺍﻟﻌﺮﻑﺍﻟﺤﺮﻗﻔﻲﺗﺤﺖﺍﻟﺘﺨﺪﻳﺮﺍﻟﻜﻠﻲﺃﻭﺍﻟﻤﻮﺿﻌﻲ
ﻟﻠﻤﺘﺒﺮﻉ.ﻭﻟﻜﻦ،ﺃﺣﺪﺙﺍﻛﺘﺸﺎﻑﻃﺮﻳﻘﺔﺗﺠﻤﻴﻊﺍﻟﺨﻼﻳﺎﺍﻟﺠﺬﻋﻴﺔﻣﻦﺍﻟﺪﻡﺍﻟﻤﺤﻔﺰﺓ
ﺑﻌﺎﻣﻞﺗﻨﺸﻴﻂﻟﻨﺨﺎﻉﺍﻟﻌﻈﻢ،ﻧﻘﻠﺔﻧﻮﻋﻴﺔﻓﻲﻣﺠﺎﻝﺯﺭﺍﻋﺔﺍﻟﺨﻼﻳﺎﺍﻟﺠﺬﻋﻴﺔ
ﻭﻧﺘﺎﺋﺠﻬﺎ.ﻓﻬﺬﻩﺍﻟﻄﺮﻳﻘﺔﻣﺮﻳﺤﺔﻟﻠﻤﺘﺒﺮﻉﻭﺗﺠﻨﺒﻪﺍﻟﺘﻌﺮﺽﻟﻠﺘﺨﺪﻳﺮﻭﺍﻟﺤﺎﺟﺔﻟﺪﺧﻮﻝ
ﺍﻟﻤﺴﺘﺸﻔﻰ.ﺗﺨﺘﻠﻒﻣﻜﻮﻧﺎﺕﺍﻟﺘﻄﻌﻴﻢﺍﻟﻤﺠﻤﻊﻣﻦﺍﻟﻤﺘﺒﺮﻉﺍﻟﺬﻱﻳﺤﺘﻮﻱﻋﻠﻰﺍﻟﺨﻼﻳﺎ
ﺍﻟﺠﺬﻋﻴﺔﺑﺎﺧﺘﻼﻑﺍﻟﻤﺼﺪﺭ،ﺣﻴﺚﺃﻥﻛﻞﻣﺼﺪﺭﻟﻪﺗﺄﺛﻴﺮﺇﻳﺠﺎﺑﻲﺃﻭﺳﻠﺒﻲﻋﻠﻰ
ﻧﺘﺎﺋﺞﺯﺭﺍﻋﺘﻪﺑﺎﻟُﻤﺘﺒﺮﻉﻟﻪ.ﻭﺑﻤﺎﺃﻥﺯﺭﺍﻋﺔﺍﻟﺨﻼﻳﺎﺍﻟﺠﺬﻋﻴﺔﺍﻟُﻤﺠﻤﻌﺔﻣﻦﺍﻟﺤﺒﻞ
ﺍﻟﺴﺮﻱﺗﻌﺘﺒﺮﻓﻲﺑﺪﺍﻳﺎﺗﻬﺎ،ﻓﺈﻥﻋﺪﺩﻣﻦﺍﻟﺪﺭﺍﺳﺎﺕﺍﻟﻌﻠﻤﻴﺔﺧﻼﻝﺍﻟﺴﻨﻮﺍﺕﺍﻟﻤﺎﺿﻴﺔ
ﺭﻛﺰﻋﻠﻰﻣﻘﺎﺭﻧﺔﻧﺘﺎﺋﺞﺯﺭﺍﻋﺔﺍﻟﺘﻄﻌﻴﻢﻣﻦﺍﻟﺨﻼﻳﺎﺍﻟﺠﺬﻋﻴﺔﺍﻟﻤﺤﻔﺰﺓﻣﻦﺍﻟﺪﻡ
ﺑﺰﺭﺍﻋﺔﺍﻟﺘﻄﻌﻴﻢﻣﻦﻧﻘﻲﺍﻟﻌﻈﻢﻋﻠﻰﺍﻟُﻤﺘﺒﺮﻉﻟﻪﻭﻣﺤﺎﻭﻟﺔﺗﺤﺪﻳﺪﺃﻳﻬﻤﺎﺃﻓﻀﻞ.ﻣﻦ
ﺧﻼﻝﻫﺬﻩﺍﻟﻤﺮﺍﺟﻌﺔﺍﻟﺒﺤﺜﻴﺔﺭﻛﺰﻧﺎﻋﻠﻰﻣﻘﺎﺭﻧﺔﺯﺭﺍﻋﺔﺍﻟﺘﻄﻌﻴﻢﻣﻦﺍﻟﺨﻼﻳﺎ
ﺍﻟﺠﺬﻋﻴﺔﺍﻟﻤﺤﻔﺰﺓﻣﻦﺍﻟﺪﻡﺑﺰﺭﺍﻋﺔﺍﻟﺘﻄﻌﻴﻢﻣﻦﻧﻘﻲﺍﻟﻌﻈﻢﻋﻠﻰﺍﻟﻤﺘﺒﺮﻋﻴﻦﻭﺗﺄﺛﻴﺮﻫﺎ
ﻋﻠﻰﺍﻟﻨﺘﺎﺋﺞﺍﻟﺴﺮﻳﺮﻳﺔﻟﻠُﻤﺘﺒﺮﻉﻟﻬﻢﺑﻌﺪﻋﻤﻠﻴﺔﺍﻟﺰﺭﺍﻋﺔ.
ﺍﻟﻜﻠﻤﺎﺕﺍﻟﻤﻔﺘﺎﺣﻴﺔ:ﺯﺭﺍﻋﺔﻧﻘﻲﺍﻟﻌﻈﻢ;ﺩﺍﺀﺍﻟﻄﻌﻢﺣﻴﺎﻝﺍﻟﺜﻮﻱ;ﺯﺭﺍﻋﺔﻣﻜﻮﻧﺎﺕﺍﻟﺪﻡ;
ﻣﺘﺒﺮﻉﻗﺮﻳﺐﻣﺘﻄﺎﺑﻖ;ﺍﻟﺨﻼﻳﺎﺍﻟﺠﺬﻋﻴﺔﻣﻦﺍﻟﺪﻡﺍﻟﻤﺤﻔﺰ;ﻣﺘﺒﺮﻉﻏﻴﺮﻗﺮﻳﺐ
Abstract
Bone marrow (BM), granulocyte-colony stimulating factor
mobilized peripheral blood stem cells (PBSC) and cord
blood are the 3 sources of stem cells for allogeneic hemato-
poietic cell transplantation (HCT) that have been used to
cure hematological malignancies and other disorders. Bone
marrow obtained by repeated aspiration of the posterior
iliac crests while the donor is under general or local anesthe-
sia was the first source of hematopoietic stem cells. Intro-
duction of PBSC as a source of stem cells resulted in
important changes in transplant practices and outcomes.
PBSC harvesting is more convenient for the donors with
the advantage of avoiding anesthesia and hospitalization.
There are differences in the composition of the graft sources
that are reflected in different clinical outcomes both favor-
able and unfavorable. While the field of cord blood trans-
plant is still in its infancy, there has been over the years
many studies aimed at determining whether BM or PBSC
grafts are superior. This review article summarizes our cur-
rent knowledge on clinical outcomes between allogeneic
transplants performed with peripheral blood stem cells
(PBSC) and bone marrow (BM).
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Introduction
Allogeneic hematopoietic cell transplant (HCT) became feasi-
ble in the early 1960s after the identification and typing of Hu-
man Leukocyte Antigens (HLA), the major histocompatibility
complex.1–4 Allogeneic HCT is now a standard therapeutic ap-
proach to cure hematological malignancies and other disorders
(Figure 1).5
The practice of allogeneic HCT has evolved over the past 4
decades and in general, outcomes have also improved.6 Many
factors in addition to the graft source affect post-transplant
outcomes. In repeated studies over many years, important fac-
tors that influence post-transplant outcomes include patient
age, performance status and medical comorbidities, diagnosis
and disease stage, other characteristics of the disease and prior
therapies, degree of HLA compatibility (related and unrelated
donors), recipient and donor gender mismatch, GVHD pro-
phylaxis, the intensity of the conditioning regimen, graft com-
position and cell (CD34+) dose and various aspects of
supportive care.1–4,7–17 Many of these variables are not modi-
fiable while some can be improved by better patient selection.
One aspect of the transplant, graft type, has received signifi-
cant attention both in large observational registry studies as
well as large randomized clinical trials. These studies have
looked at the important clinical outcomes of morbidity, acute
and chronic GVHD, disease control, survival and other impor-
tant clinical outcomes (Table 1).1
Donating BM versus PBSC
In the beginning, all transplants used a bone marrow (BM)
graft and all transplants were from matched sibling donors.
BM was obtained by repeated aspiration of the posterior iliac
crests with the donor under general or local anesthesia and
was infused unmanipulated other than for red cell and possi-
bly volume depletion. The discovery that granulocyte colony
stimulating factor (G-CSF) could increase and mobilize the
cells of interest from the bone marrow into the peripheral
blood in large numbers led to a rapid adoption of this graft
source. While initially applied in the autologous setting, it
was not long until PBSC were applied in the allogeneic set-
ting.18–20 PBSC harvesting is more convenient for donors
with the advantage of avoiding anesthesia and hospitalization
and is associated with less morbidity.21 Furthermore, G-CSF
mobilized PBSC collection for allogeneic HCT is generally
safe and well tolerated. The most common adverse event is
bone pain in the axial skeleton, which is rarely severe
(<1%).21,22 There are other rare short-term adverse events
associated with PBSC donation because of G-CSF adminis-
tration (e.g. local reactions, severe headache, nausea, myalgia,
splenic rupture), complications associated with placement of
a CVC when peripheral access is inadequate (e.g. infection,
bleeding, pneumothorax), and/or problems with leukapheresis
(e.g. bleeding secondary to anticoagulation, hypocalcemia
due to acid citrate dextrose [ACD] use).21 A prospective ran-
domized trial (RCT), that compared donation of BM versus
G-CSF mobilized PBSC in HLA-matched sibling donors
(MRD), showed BM donors had more fatigue and less en-
ergy than the PBPC donors post donation. BM donors but
not PSBSC donors also had compromised quality of life
(QoL) up to 1 month after donation.22 Although theoretical
concerns have been raised about G-CSF contributing to an
increased risk of myeloid malignancies in healthy donors,
an increase has not been seen in several small prospective
and large retrospective studies of G-CSF treated do-
nors.21,23–25
Figure 1: Indication of hematopoietic stem cell transplantation (HCT) in US, 2010 (CIBMTR registry).2
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PBSC vs. BM in allogeneic HCT from HLA-matched related
donor (MRD)
As stated above, the adoption of PBSC as a graft source for
MRD allogeneic transplant was rapid and common. Registry
data and surveys demonstrated increased use of PBSCs as
the graft source for allogeneic hematopoietic cell transplants
(HCT) that ranged between 50% and 80% (Figure 2), with
much of the adoption predating definitive trial data.5,26 Fol-
lowing several case series and registry studies suggesting bene-
fits to PBSC, several randomized trials compared BM to PBSC
in the setting of myeloablative conditioning regimen trans-
plants from MRD. All trials reported PBSC graft associated
with faster neutrophil and platelet engraftment compared to
a BM graft in this setting.27–33 The impact on treatment related
mortality (TRM), relapse, GVHD and survival was more
mixed. Bensinger reported the first RCT of 172 patients
(12–55 years of age) with hematologic cancer.27,28 Patients
were randomized to receive BM or PBSC grafts following
myeloablative (MA) conditioning regimens. This study showed
no significant difference in incidence of grade > I acute
GVHD at 100 days, chronic GVHD or 2 year overall survival
(OS) between the groups. The 2 year disease free survival
(DFS), however, was superior with PBSC compared to BM
(66% vs. 45%; respectively, P= 0.03). A follow up report
with a median follow up of 12.2 years confirmed superior
DFS with PBSC compared with BM.29 The estimated 10-year
probability of relapse of primary disease was 20% with PBSC
compared to 32% with BM (P= 0.01). Once again, however,
the OS, incidence of chronic GVHD and the duration of sys-
temic immunosuppressive therapy (IST) were similar in the
groups. Quality of life data was not reported for surviving
patients. A second RCT reported by Couban and colleagues
included 228 patients with myeloid malignancies randomized
to BM or PBSC from an HLA MRD.30 All patients received
busulfan and cyclophosphamide (BU/Cy) as pre-transplant
conditioning therapy and cyclosporine (CSA) plus short course
Methotrexate (MTX) as GVHD prophylaxis. Contrary to the
Bensinger study, the 30 month OS was superior in the PBSC
group compared to the BM group (68% vs. 60%; P= 0.04).
The cumulative incidence of grades II to IV acute GVHD
100 days after transplantation, extensive chronic GVHD at
30 months and relapses were similar in both groups.
More recently the Stem Cell Trialists’ Collaborative Group
reported a meta-analysis using data from nine RCTs including
the 2 outlined above.31 The studies included 1111 adult pa-
tients with hematologic malignancies randomly assigned to re-
ceive a BM or PBSC graft from a MRD between 1990 and
2003. Results of the meta-analysis were again mixed and at
times surprising. For example, non-relapse mortality (NRM)
was similar between groups. PBSC transplants were associated
with a significant increase of grade 3–4 acute GVHD but not
grade 2–4 acute GVHD at 3 years compared to BM trans-
plants (47% vs. 31% and 54% vs. 53%, respectively). More
importantly, and in keeping with clinicians’ impressions, the
incidence of chronic GVHD at 3 years was higher with PBSC
compared to BM (68% vs. 52%, respectively; P< 0.000001).
A DFS and OS benefit with PBSC was only seen in patients
with late-stage disease (41% vs. 27%; P= 0.01 and 46% vs.
31%; P= 0.01, for PBSC vs. BM, respectively). Late-stage
disease was defined as chronic myelogenous leukemia more
than chronic phase-1 (CML> CP-1), acute myeloid leukemia
more than first complete remission (AML> CR1),
myelodysplastic syndrome with excess blast or in transforma-
tion (RA-EB or RA-EB in transformation). A subsequent
meta-analysis of 10 RCTs, not surprisingly, reported generally
similar results for patients with hematologic malignancies
Table 1: Impact of PBSC graft compared BM graft on the outcomes of myeloablative conditioning allogeneic HCT.*
Disease Age Donor Disease stage# NRM Relapse rate aGVHD cGVHD DFS OS
Hematological
malignancies++
Adult MRD Early disease = ; = or " " = or " =
Late disease = ; = or " " " "
URD Early &
late disease
= = = " = =
Children &
adolescents
(<20 years)
MRD & URD NA$ " = = " = ;
Severe aplastic
anemia (SAA)
All ages MRD & URD NA " Equal risk of
graft rejection
" " Equal
mortality
related
to graft
rejection
;
Allogeneic HCT: allogeneic hematopoietic cell transplant, MRD: HLA-matched related donor, URD: HLA-matched unrelated donor, NRM:
non-relapse mortality, aGVHD: acute graft versus host disease, cGVHD: chronic graft versus host disease, DFS: disease-free survival, OS:
overall survival.
=: means equivalent outcomes or trials failed to show a difference.
;: means decreased or inferior results with PBSC.
": means increased or superior results with PBSC.
* Other factors affecting the outcomes of allogeneic HCT include patient age, performance status and comorbidity, primary disease type,
cytogenetics and stage, HLA compatibility (related and unrelated donors), gender mismatch, GVHD prophylaxis, conditioning regimens, and
time of transplant.
++ Hematological malignancies: AML, ALL, CML, MDS, CMML, and myelofibrosis.
# Late-stage disease was defined as CML> CP-1, AML> CR1, and MDS; RA-EB or RA-EB in transformation.
$ NA: not available.
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(n= 1224) with the important exception that OS was not dif-
ferent between the groups.32
One caveat is that these trials included significant numbers
of patients with chronic myeloid leukemia (CML); often in the
range of 40–50% of the trial population. This disease has been
demonstrated to be particularly amenable to the graft-versus-
leukemia allograft effect and may have ‘‘over-estimated” the
benefit of PBSC compared to BM based on higher numbers
of T-lymphocytes in PBSC grafts. This limits to some degree
the applicability of these results to present patient populations
as allogeneic transplant for CML has essentially been replaced
by oral tyrosine kinase inhibitors (TKIs) leaving patients with
other, less immunologically sensitive myeloid malignancies to
undergo allogeneic transplants.34
The interpretation and application of the above data favors
the use of BM grafts for adult patients undergoing HLA
matched related donor transplants for myeloid malignancies
as survival is the same or very similar to PBSC transplants
but with less chronic GVHD and potentially less severe acute
GVHD.27–32 For patients with advanced disease, PBSC may
be chosen with hopes of obtaining an enhanced graft-versus-
leukemia effect.31
PBSC vs. BM in allogeneic HCT from HLA-match-unrelated
donor (URD)
In part based on convenience and the short-term advantages
with PBSC seen in the related setting such as more rapid
engraftment and potentially decreased early morbidity, the
use of PBSC grafts for unrelated transplants dramatically in-
creased over the past decade in the absence of comparative
data. However, the results obtained with allogeneic HCT from
HLA-identical siblings (MRD) may not necessarily extrapo-
late to the unrelated setting due in part to the higher risk of
GVHD in the HCT from URD, even if the donor and recipient
are fully HLA-matched.1–3,33
Multiple retrospective studies in the unrelated donor setting
have demonstrated that PBSC grafts were associated with a
higher incidence of chronic GVHD, similar relapse rates and
no survival advantage compared to BM.35–37 More recently,
Anasetti and colleagues reported the outcomes of a large mul-
ticenter Phase III RCT (BMT CTN Protocol 0201) conducted
by the North American BMT Clinical Trials Network.33 This
trial randomized 551 patients with hematologic malignancies
to receive either PBSC (n= 273) or BM (n= 278) grafts from
URDs. Forty-seven percent of the patients had AML and 28%
had high-risk disease. PBSC recipients received significantly
more CD34+ cells compared to BM recipients (7.70 vs.
2.75  106/kg for PBSC vs. BM, respectively). The primary
outcome in the trial, 2 year OS was not different between the
groups. The incidence of acute GVHD and relapse rate were
not significantly different between the groups. PBSC grafts
compared to BM grafts were associated with less incidence
of graft failure (3% vs. 9%; respectively, P= 0.002) and
importantly, a higher incidence of chronic GVHD at 2 years
(53% vs. 41%; respectively, P= 0.01). Moreover, extensive
chronic GVHD was 48% with the PBSC grafts compared to
32% in BM grafts (P< 0.001). This study showed no survival
differences according to graft source in planned subset analy-
ses of patients with low and high risk malignancy or in those
who received HLA-matched or mismatched grafts. Quality
of life data is yet to be reported from this study. The absence
of a survival advantage and a higher incidence of potentially
debilitating chronic GVHD with PBSC grafts support the
use of BM grafts for this patient population.33,35–37
PBSC vs. BM in allogeneic HCT using non-myeloablative
(NMA) or reduced intensity conditioning (RIC)
The therapeutic effect of standard myeloablative allogeneic
HCT is mediated by administration of high dose chemother-
apy and/or radiation therapy (cytotoxic effect) and induction
of an immune mediated graft versus tumor effect (immunotox-
ic effect).38 The high-dose chemo-radiotherapy does not erad-
icate the malignancy in many patients and the therapeutic
benefit of allogeneic HCT is dependent in varying degrees to
the associated immune-mediated graft-versus-malignancy
effect.38,39 In the last 15 years novel agents that are less toxic
but very immune suppressive have led to the development of
ablative but less toxic ‘‘reduced intensity” and the very low
Figure 2: Graft source for allogeneic HCT by recipient age; between 2001 and 2010 (CIBMTR registry).2
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intensity ‘‘non-myeloablative” conditioning regimens. Assign-
ment to these categories is based on the duration of cytopenia
and on the requirement for hematopoietic stem cell (HSC) sup-
port.40 MA regimens cause irreversible cytopenia and HSC
support is mandatory. NMA regimens cause minimal cytope-
nia, and can be given also without HSC support. RIC regimens
do not fit criteria for MA or NMA regimens; they cause cyto-
penia of variable duration, and should be given with HSC sup-
port, although cytopenia may not be irreversible.
NMA and RIC allogeneic HCT have been reported to have
better early tolerability but rely almost entirely on the graft-
versus-tumor effect to cure patients.41–49 They have yet to be
shown to result in a definitive survival advantage in patients
who would traditionally receive an ablative conditioning
regimen.8,50–53 They have however, allowed transplants to be
offered to older and less robust patients.
There are limited quality data evaluating the impact of graft
source in the setting of RIC or NMA transplants. One retro-
spective trial by Nagler and colleagues looked at the impact
of the graft source (PBSCs vs. BM) in 602 patients with
AML in complete remission who received RIC-allogeneic
HCT from HLA-matched URD.54 This study showed the
PBSC grafts were associated with significantly higher incidence
of acute GVHD and NRM, lower incidence of relapse but no
statistically different leukemia free survival (LFS) when com-
pared to BM graft.
The risk of graft failure is related to a complex mix of
factors including prior therapy, disease status, conditioning
regimen intensity, GVHD prophylaxis, donor type, degree
of HLA match and graft source.55–57 Early case series or sin-
gle arm studies demonstrated a higher risk of graft rejection
with some approaches to RIC or NMA transplantation and
in patients with limited prior therapy.58–60 Given the risk of
graft failure with a BM graft in NMA and RIC-allogeneic
HCT, many transplant centers prefer PBSC as the graft
source, accepting the potential increase risk of chronic
GVHD. However, in the absence of prospective comparative
data the optimal graft source for NMA and RIC allogeneic
HCT remains unknown.
PBSC vs. BM in allogeneic HCT for children and adolescents
PBSC allogeneic HCT are associated with inferior outcomes
compared to BM transplants in children and adolescents.61–
63 Eapen and colleagues reported the outcomes of PBSC and
BM transplants from MRD in children aged 8–20 years with
acute leukemia from the Center for International Blood and
Marrow Transplant Research (CIBMTR) registry.61 The risks
of grade 2–4 acute GVHD were similar between the groups but
the risk of chronic GVHD at 3 years was higher after the
PBSC transplants compared to BM transplants (33% vs.
19%, respectively; P= 0.001). In addition, PBSC grafts were
associated with higher TRM, treatment failure, and mortality.
The 3-year OS in PBSC transplants was 48% compared to
58% with BM transplant (P= 0.01). Similarly, a recent retro-
spective study showed increased chronic GVHD and worse
survival with PBSC grafts compared to BM grafts for MRD
allogeneic HCT in Japanese children with acute leukemia.62
The 5-year OS was significantly lower after PBSC transplants
compared to BM transplants for ALL (42.4% vs. 63.7%,
P= 0.003) and AML (49.8% vs. 71.8%, P= 0.016).
PBSC vs. BM in allogeneic HCT for patients with aplastic
anemia
Severe aplastic anemia (SAA) is an immune-mediated disor-
der; T lymphocytes inhibit or destroy hematopoietic progeni-
tor cells resulting in marrow failure.64 Treatment options
include immune suppressive therapy (IST) with ATG and
cyclosporine and allogeneic HCT depending on the patient’s
age and matched donor availability. When an HLA-matched
sibling is lacking or the patient is >40 years old, IST is the rec-
ommended first-line treatment with HCT reserved for those
patients who fail IST.64,65 Multiple studies have demonstrated
that bone marrow is preferred as the graft source for patients
with aplastic anemia as PBSC grafts are associated with worse
transplant outcomes compared to BM grafts.63–68
For example, Schrezenmeier reported combined CIBMTR
and European Bone Marrow Transplant (EBMT) data that
showed a higher incidence of chronic GVHD and higher mor-
tality with PBSC compared to BM grafts in SAA patients
younger than 20 years of age receiving a first allogeneic HCT
from HLA-MRD (relative risk (RR), 2.82; P= 0.002 and
RR, 2.04; P= 0.024, respectively).63 In younger patients, the
5-year OS was 73% and 85% after PBSC and BM transplants,
respectively. In this study, chronic GVHD and overall mortal-
ity rates were similar after PBSC and BM transplants in pa-
tients older than 20 years. Higher chronic GVHD after
PBPC transplants in younger patients likely contributed to
the excess mortality. Similarly, Bacigalupo reported a large
registry study of combined CIBMTR and EBMT data analyz-
ing outcomes of MRD allogeneic transplants for SAA.66 This
study compared outcomes of patients with SAA who received
a first HCT from a HLA-MRD with either a BM (n= 1163)
or PBSC (n= 723) graft. The incidence of acute and chronic
GVHD was higher with PBSC grafts. More importantly, sur-
vival was inferior with PBSC grafts compared to BM grafts
in patients younger than 20 (76% vs. 90%; respectively,
P< 0.00001) as well as in patients older than 20 years (64%
vs. 74%; respectively, P= 0.001). Chu and colleagues from
CIBMTR published similar findings of higher rates of acute
and chronic GVHD in PBSC recipients compared to BM
recipients in patients who underwent an HLA-MRD trans-
plant for SAA.67
In terms of HLA-matched URD allogeneic transplant for
SAA, Eapen and colleagues reported higher mortality, inde-
pendent of age, with PBSC grafts compared to BM grafts in
296 patients with SAA that included both pediatric and adult
patients.68 In this retrospective study, grade 2–4 acute GVHD
was higher with PBSC grafts compared to BM grafts. How-
ever, hematopoietic recovery and chronic GVHD risks were
not significantly different between the groups.
In summary, for SAA in both children and adults whether
from an HLA-MRD or MUD, bone marrow is the preferred
graft source.
Ongoing graft source research
One approach to try and achieve the benefits of both
BM grafts (lower chronic GVHD) and PBSC grafts (faster
engraftment and perhaps enhanced GVL) has been the use
of HSC collected from a bone marrow after the donor has been
given G-CSF to ‘‘prime” the bone marrow (G-BM).69–71 A
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large Canadian trial comparing G-BM to PBSC in related do-
nor transplants has recently completed accrual and should pro-
vide important comparative data in the near term.
Plerixafor is a recently approved drug used to mobilize HSC
from themarrow in the autologous transplant setting. Plerixafor
is a newHSCmobilizing drug that antagonizes the binding of the
chemokine stromal-cell-derived factor-1alpha (SDF-1alpha) to
CXC chemokine receptor 4 (CXCR4).72 This drug is able to
mobilize HSC when G-CSF or chemotherapy + G-CSF have
failed andpre-clinical studies suggest that itmay produce a supe-
rior stem cell graft toG-CSF alone. Plerixafor when used in con-
junction with G-CSF as a PBSCmobilization agent has allowed
more patients with multiple myeloma, non-Hodgkin’s lym-
phoma, and Hodgkin’s disease to mobilize sufficient HSC to
proceed to autologous HCT.73–76 Plerixafor is now under inves-
tigation for HSC collection from healthy donors for allogeneic
HCT.Also of interest, there is an ongoing phase I/II study to test
the safety and efficacy of post-transplant administration of pler-
ixafor to enhance donor hematopoietic cell engraftment after
myeloablative allogeneic HCT (NCT01280955).
Summary and conclusion
Many factors besides the graft source affect the short-term and
long-term outcomes of allogeneic HCT including patient’s age,
performance status and medical comorbidities, diagnosis and
disease status, donor type, degree of HLA match, gender mis-
match, GVHD prophylaxis, intensity of the conditioning regi-
mens, graft composition and cell (CD34+) dose.1–4,7–17 In
HLA-MRD and URD with myeloablative conditioning regi-
mens, bone marrow is the preferred graft source as it is associ-
ated with similar survival but less risk for chronic GVHD
compared to PBSC.31–33 With advanced or poor-risk disease,
PBSC may offer the potential of improved DFS and OS.27,31
In some settings, allogeneic HCT for hematological malig-
nancies using NMA and RIC results in reduced early treat-
ment related morbidity and treatment related mortality
compared to standard myeloablative conditioning without a
survival advantage or difference in the incidence of chronic
GVHD.8,50–53 They have, however, extended the transplant
option to older and more medically complex patients. In gen-
eral, PBSCs for RIC-allogeneic HCT are associated with a
lower risk of graft failure compared to BM graft.54–60
Although general clinical practice favors PBSC for NMA
and RIC allogeneic transplants, this remains a preference in
the absence of prospective comparative data.
Bone marrow grafts are preferred for allogeneic HCT in
children and adolescents with hematologic malignancies.61,62
Finally, patients with SAA of all ages undergoing an allogeneic
HCT should receive bone marrow grafts.63–68
Future research through registry studies and clinical trials
will continue to explore differences between these graft
sources. Two areas of interest remain trying to find the best
of both graft types, perhaps with G-CSF primed BM and ways
to facilitate the donor process perhaps with the use of novel
mobilizing agents such as plerixafor.
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